Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.
Combination therapy with the HIF-2α inhibitor belzutifan and the multikinase inhibitor cabozantinib shows antitumor activity in people with metastatic clear cell renal cell carcinoma, phase 2 study data show.
A number of baseline variables, including age and PD-L1 expression level, may be linked to survival outcomes among people receiving PD-1 or PD-L1 inhibitors for metastatic clear cell renal cell carcinoma, meta-analysis data show.
Treatment with cabozantinib gives patients with advanced renal cell carcinoma significantly more time without disease progression and toxicity relative to treatment with sunitinib, CABOSUN trial data show.
A phase 2 trial update for hypoxia-inducible factor-2α inhibitor MK-6482 in patients with treatment-naïve renal cell carcinoma associated with von Hippel-Lindau disease has been presented at the ESMO Virtual Congress 2020.
The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.
Real-world study data show that a high proportion of patients with metastatic clear cell renal cell carcinoma gain clinical benefit from treatment with cabozantinib following progression with immune checkpoint inhibitors.
The combination of nivolumab and ipilimumab demonstrates antitumor activity and acceptable toxicity in patients with metastatic renal cell carcinoma previously exposed to PD-1 or PD-L1 inhibitors, say the authors of a chart review.